结果:病例组受试者红细胞C3b受体花环率明显低于对照组(10.81%±2.01% vs 18.06%±3.44%),红细胞免疫复合物花环率明显高于对照组(17.21±3.49% vs 11.74±2.14%),血清EPO浓度明显高于对照组(26.10±5.22 mU/mL vs 22.68±4.06mU/mL),血浆ET-1浓度明显高于对照组(70.85±7.16ng/L vs 58.43±5.09ng/L)。闭角型青光眼患者红细胞C3b受体花环率与血清EPO浓度呈显著正相关(r=0.271,P<0.05),与血浆ET-1浓度无明显相关性。
AbstractPancreatic cancer is one of the deadliest cancers across the world with an average 5-year survival rate of less than <6%. In this study, gemcitabine (GEM) and HIF1α-siRNA loaded GE-11 peptide conjugated liposome was successfully prepared and evaluated for its antitumor efficacy in pancreatic cancer cells. The GE11 increased the targeting specificity of liposome carrier and increased the intracellular concentrations in the cancer cells. Furthermore, synergistic combination of GEM and HIF1a-siRNA exhibited remarkable improvement in the declining of cancer cell proliferations. siRNA could effectively decrease the expression of HIF1a gene in the cancer cells. Importantly, GE-11 peptide-conjugated GEM/siRNA-loaded liposomes (GE-GML/siRNA) increased the total amount of apoptosis cells with higher proportion of cells in late apoptosis phase. GE-GML induced remarkable apoptosis of cancer cells and induced chromatin condensation and nuclear fragmentation which are considered to be typical features of apoptosis and cell death. GE-GML/siRNA showed a significant reduction in the tumour burden suggesting the superior anticancer efficacy of this formulation. GE-GML/siRNA showed four-fold reduction in tumour compared to control and two-fold reduction compared to GE-GML, respectively. Overall, present work lays foundation for the combination of GEM and HIF1a-siRNA loaded in a targeted nanocarrier system as a unique therapeutic option in pancreatic cancer treatment. 相似文献